Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

Status Recruiting

Clinical Trial Summary

Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE).

Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye

Clinical Trial Description

n/a

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01626339
Study type	Interventional
Source	University of Malaya
Contact	Mohammadreza Peyman, MD
Phone	0060173387260
Email	drmpeyman@yahoo.com
Status	Recruiting
Phase	N/A
Start date	April 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03963817` - Snapshot Camera for AMD
Recruiting	`NCT04929756` - Eye Movement Rehabilitation in Low Vision Patients
Completed	`NCT04779398` - Association of MPOD Values With Blue Light.
Terminated	`NCT03275753` - Visual Function Tests in Age-related Macular Degeneration
Recruiting	`NCT03609307` - Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial	Phase 2/Phase 3
Completed	`NCT02909985` - Visual Activity Evoked by Infrared in Humans After Dark Adaptation	N/A
Completed	`NCT02556723` - Intravitreal Injections of Ziv-aflibercept for Macular Diseases	N/A
Active, not recruiting	`NCT01943396` - Treatment of AMD With Rheohemapheresis /RHF/	Phase 4
Completed	`NCT00963339` - Age-Related Macular Degeneration (AMD) - Usability Study	N/A
Completed	`NCT00376701` - Combination Therapy for Age-Related Macular Degeneration.	Phase 2
Completed	`NCT00800995` - Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)	Phase 3
Terminated	`NCT00347165` - Intravitreal Bevacizumab for Age-Related Macular Degeneration	Phase 2
Completed	`NCT04689789` - OCTA and Retinal Angiomatous Proliferation
Completed	`NCT02567604` - Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
Completed	`NCT02173496` - Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
Recruiting	`NCT01991730` - Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients	N/A
Active, not recruiting	`NCT01657669` - Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results	Phase 4
Completed	`NCT00791570` - Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy	Phase 1
Completed	`NCT00776763` - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab	Phase 2
Completed	`NCT00413829` - Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)	Phase 2